Research and Development Expense in USD of Anixa Biosciences Inc from Q2 2010 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Anixa Biosciences Inc quarterly/annual Research and Development Expense history and change rate from Q2 2010 to Q2 2025.
  • Anixa Biosciences Inc Research and Development Expense for the quarter ending 31 Jul 2025 was $1,055,000.000, a 45.2% decline year-over-year.
  • Anixa Biosciences Inc Research and Development Expense for the twelve months ending 31 Jul 2025 was $5,405,000.000, a 17.3% decline year-over-year.
  • Anixa Biosciences Inc annual Research and Development Expense for 2024 was $6,396,000.000, a 34.1% increase from 2023.
  • Anixa Biosciences Inc annual Research and Development Expense for 2023 was $4,769,000.000, a 28.9% decline from 2022.
  • Anixa Biosciences Inc annual Research and Development Expense for 2022 was $6,703,000.000, a 8.29% increase from 2021.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

Anixa Biosciences Inc Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $5,405,000 $1,055,000 -$870,000 -45.2% 01 May 2025 31 Jul 2025 10-Q 10 Sep 2025
Q1 2025 $6,275,000 $1,322,000 -$324,000 -19.7% 01 Feb 2025 30 Apr 2025 10-Q 28 May 2025
Q4 2024 $6,599,000 $1,552,000 +$203,000 +15% 01 Nov 2024 31 Jan 2025 10-Q 11 Mar 2025
Q3 2024 $6,396,000 $1,476,000 -$139,000 -8.6% 01 Aug 2024 31 Oct 2024 10-K 10 Jan 2025
Q2 2024 $6,535,000 $1,925,000 +$837,000 +76.9% 01 May 2024 31 Jul 2024 10-Q 10 Sep 2025
Q1 2024 $5,698,000 $1,646,000 +$648,000 +64.9% 01 Feb 2024 30 Apr 2024 10-Q 28 May 2025
Q4 2023 $5,050,000 $1,349,000 +$281,000 +26.3% 01 Nov 2023 31 Jan 2024 10-Q 11 Mar 2025
Q3 2023 $4,769,000 $1,615,000 -$70,000 -4.2% 01 Aug 2023 31 Oct 2023 10-K 10 Jan 2025
Q2 2023 $4,839,000 $1,088,000 -$357,000 -24.7% 01 May 2023 31 Jul 2023 10-Q 06 Sep 2024
Q1 2023 $5,196,000 $998,000 -$737,000 -42.5% 01 Feb 2023 30 Apr 2023 10-Q 04 Jun 2024
Q4 2022 $5,933,000 $1,068,000 -$770,000 -41.9% 01 Nov 2022 31 Jan 2023 10-Q 12 Mar 2024
Q3 2022 $6,703,000 $1,685,000 -$488,000 -22.5% 01 Aug 2022 31 Oct 2022 10-K 16 Jan 2024
Q2 2022 $7,191,000 $1,445,000 -$722,000 -33.3% 01 May 2022 31 Jul 2022 10-Q 06 Sep 2023
Q1 2022 $7,913,000 $1,735,000 +$713,000 +69.8% 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023
Q4 2021 $7,200,000 $1,838,000 +$1,010,000 +1.2% 01 Nov 2021 31 Jan 2022 10-Q 17 Mar 2023
Q3 2021 $6,190,000 $2,173,000 +$1,765,304 +4.3% 01 Aug 2021 31 Oct 2021 10-K 04 Jan 2023
Q2 2021 $4,424,696 $2,167,000 +$912,869 +72.8% 01 May 2021 31 Jul 2021 10-Q 09 Sep 2022
Q1 2021 $3,511,827 $1,022,000 -$206,790 -16.8% 01 Feb 2021 30 Apr 2021 10-Q 10 Jun 2022
Q4 2020 $3,718,617 $828,000 -$662,588 -44.5% 01 Nov 2020 31 Jan 2021 10-Q 11 Mar 2022
Q3 2020 $4,381,205 $407,696 -$463,492 -53.2% 01 Aug 2020 31 Oct 2020 10-K 04 Jan 2022
Q2 2020 $4,844,697 $1,254,131 +$168,557 +15.5% 01 May 2020 31 Jul 2020 10-Q 01 Sep 2021
Q1 2020 $4,676,140 $1,228,790 -$40,603 -3.2% 01 Feb 2020 30 Apr 2020 10-Q 10 Jun 2021
Q4 2019 $4,716,743 $1,490,588 -$756,684 -33.7% 01 Nov 2019 31 Jan 2020 10-Q 11 Mar 2021
Q3 2019 $5,473,427 $871,188 -$1,561,718 -64.2% 01 Aug 2019 31 Oct 2019 10-K 07 Jan 2021
Q2 2019 $7,035,145 $1,085,574 -$1,856,497 -63.1% 01 May 2019 31 Jul 2019 10-Q 08 Sep 2020
Q1 2019 $8,891,642 $1,269,393 +$609,200 +92.3% 01 Feb 2019 30 Apr 2019 10-Q 09 Jun 2020
Q4 2018 $8,282,442 $2,247,272 +$1,469,399 +1.9% 01 Nov 2018 31 Jan 2019 10-Q 09 Mar 2020
Q3 2018 $6,813,043 $2,432,906 +$2,081,078 +5.9% 01 Aug 2018 31 Oct 2018 10-K 09 Jan 2020
Q2 2018 $4,731,965 $2,942,071 +$2,579,103 +7.1% 01 May 2018 31 Jul 2018 10-Q 06 Sep 2019
Q1 2018 $2,152,862 $660,193 +$229,069 +53.1% 01 Feb 2018 30 Apr 2018 10-Q 12 Jun 2019
Q4 2017 $1,923,793 $777,873 +$326,243 +72.2% 01 Nov 2017 31 Jan 2018 10-Q 13 Mar 2019
Q3 2017 $1,597,550 $351,828 -$61,928 -15% 01 Aug 2017 31 Oct 2017 10-K 11 Jan 2019
Q2 2017 $1,659,478 $362,968 +$70,905 +24.3% 01 May 2017 31 Jul 2017 10-Q 07 Sep 2018
Q1 2017 $1,588,573 $431,124 +$38,535 +9.8% 01 Feb 2017 30 Apr 2017 10-Q 11 Jun 2018
Q4 2016 $1,550,038 $451,630 -$6,421 -1.4% 01 Nov 2016 31 Jan 2017 10-Q 09 Mar 2018
Q3 2016 $1,556,459 $413,756 01 Aug 2016 31 Oct 2016 10-K 09 Jan 2018
Q2 2016 $292,063 01 May 2016 31 Jul 2016 10-Q 08 Sep 2017
Q1 2016 $392,589 01 Feb 2016 30 Apr 2016 10-Q 26 May 2017
Q4 2015 $458,051 01 Nov 2015 31 Jan 2016 10-Q 16 Mar 2017
Q3 2012 $2,211,506 $499,204 -$237,207 -32.2% 01 Aug 2012 31 Oct 2012 10-K/A 17 Jan 2014
Q2 2012 $2,448,713 $458,412 -$421,232 -47.9% 01 May 2012 31 Jul 2012 10-Q/A 20 Sep 2013
Q1 2012 $2,869,945 $604,211 -$127,595 -17.4% 01 Feb 2012 30 Apr 2012 10-Q/A 19 Jun 2013
Q4 2011 $2,997,540 $649,679 -$127,233 -16.4% 01 Nov 2011 31 Jan 2012 10-Q/A 25 Mar 2013
Q3 2011 $3,124,773 $736,411 01 Aug 2011 31 Oct 2011 10-K 29 Jan 2013
Q2 2011 $879,644 +$206,324 +30.6% 01 May 2011 31 Jul 2011 10-Q 14 Sep 2012
Q1 2011 $731,806 01 Feb 2011 30 Apr 2011 10-Q 14 Jun 2012
Q4 2010 $776,912 01 Nov 2010 31 Jan 2011 10-Q 16 Mar 2012
Q2 2010 $673,320 01 May 2010 31 Jul 2010 10-Q/A 14 Oct 2011

Anixa Biosciences Inc Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $6,396,000 +$1,627,000 +34.1% 01 Nov 2023 31 Oct 2024 10-K 10 Jan 2025
2023 $4,769,000 -$1,934,000 -28.9% 01 Nov 2022 31 Oct 2023 10-K 10 Jan 2025
2022 $6,703,000 +$513,000 +8.3% 01 Nov 2021 31 Oct 2022 10-K 16 Jan 2024
2021 $6,190,000 +$1,808,795 +41.3% 01 Nov 2020 31 Oct 2021 10-K 04 Jan 2023
2020 $4,381,205 -$1,092,222 -20% 01 Nov 2019 31 Oct 2020 10-K 04 Jan 2022
2019 $5,473,427 -$1,339,616 -19.7% 01 Nov 2018 31 Oct 2019 10-K 07 Jan 2021
2018 $6,813,043 +$5,215,493 +3.3% 01 Nov 2017 31 Oct 2018 10-K 09 Jan 2020
2017 $1,597,550 +$41,091 +2.6% 01 Nov 2016 31 Oct 2017 10-K 11 Jan 2019
2016 $1,556,459 +$845,068 +1.2% 01 Nov 2015 31 Oct 2016 10-K 09 Jan 2018
2015 $711,391 01 Nov 2014 31 Oct 2015 10-K 08 Dec 2016
2012 $2,211,506 -$913,267 -29.2% 01 Nov 2011 31 Oct 2012 10-K/A 17 Jan 2014
2011 $3,124,773 +$117,314 +3.9% 01 Nov 2010 31 Oct 2011 10-K 29 Jan 2013
2010 $3,007,459 01 Nov 2009 31 Oct 2010 10-K 30 Jan 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.